Ageless Pep Academy Clinical Education · Licensed Prescribers

Weight Loss Protocol

Weight Loss Protocol

Overview

A multi-mechanism weight loss protocol combining GLP-1/GIP receptor agonist therapy (primary driver of appetite suppression and metabolic recalibration) with targeted fat-burning peptides and metabolic activators. The protocol addresses appetite, lipolysis, and metabolic rate simultaneously for superior results compared to GLP-1 therapy alone. Expected outcomes include 15-25% total body weight reduction over 12+ weeks depending on the GLP-1 agent selected, with preservation of lean mass when combined with adequate protein and resistance training.

Components

Peptide Dose Frequency Duration
Retatrutide OR Semaglutide OR Tirzepatide Titrated (start low) Weekly SubQ injection 12+ weeks
AOD-9604 250 mcg Once daily, AM fasted 12 weeks
5-Amino-1MQ 50 mg Twice daily (BID) 12 weeks

Titration example for Semaglutide:

  • Weeks 1-4: 0.25 mg/week
  • Weeks 5-8: 0.5 mg/week
  • Weeks 9-12: 1.0 mg/week (adjust based on tolerance)

Administration

  • GLP-1 agonists: Weekly SubQ injection, any site (abdomen, thigh, upper arm); rotate injection sites
  • AOD-9604: Daily SubQ injection, morning, fasted state; empty stomach required for optimal lipolytic action; wait 30-60 minutes before eating
  • 5-Amino-1MQ: Oral capsule; taken with or without food; morning and evening dosing
  • Ensure adequate hydration throughout; GLP-1 agonists can cause dehydration via nausea

Cycling

  • GLP-1 agents: Typically continued as long as clinically indicated; most patients require ongoing treatment to maintain results
  • AOD-9604: 12 weeks on / 4 weeks off
  • 5-Amino-1MQ: 12 weeks on / 4 weeks off; reassess need at each cycle

Expected Timeline

  • Week 1-4: Significant appetite reduction (GLP-1 effect); nausea adjustment period; first 2-5% weight loss
  • Week 5-8: Continued weight loss trajectory; energy improving as body adapts; AOD-9604 enhancing fat mobilization
  • Week 9-12: 10-20% total body weight reduction possible depending on agent; metabolic markers (glucose, lipids) improving
  • Beyond 12 weeks: Continued loss with maintained therapy; body recomposition phase with exercise

Monitoring

  • Weekly weight and waist circumference
  • Monthly: HbA1c, fasting glucose, lipid panel, liver enzymes
  • Watch for: nausea, vomiting, constipation (GLP-1 side effects) — manage with dose titration and dietary adjustments
  • Lean mass monitoring (DEXA) at baseline and 12 weeks — add protein intake if muscle loss detected
  • Gallbladder monitoring — rapid weight loss increases cholecystitis risk

Contraindications

  • Personal or family history of medullary thyroid carcinoma (GLP-1 agonists — black box warning)
  • Multiple Endocrine Neoplasia type 2 (MEN-2)
  • Active pancreatitis or history of severe pancreatitis
  • Pregnancy or breastfeeding
  • Active cancer

Sources

#protocol #weightloss #GLP1 #semaglutide #tirzepatide #retatrutide #AOD9604 #obesity